

**NEW TEST**

[Click for Pricing](#)

**Preeclampsia Risk Assessment (sFlt-1/PIGF Ratio)**

3017909, PERA S/P

**Specimen Requirements:**

**Patient Preparation:**

**Collect:** Serum separator tube (SST), plain red, or pink (K2EDTA)

**Specimen Preparation:** Allow serum to clot completely at room temperature. Transfer 2 mL serum or plasma (Min: 0.5 mL) to an ARUP standard transport tube.

**Transport Temperature:** Preferred transport temp: Refrigerated. Also acceptable: Frozen.

**Unacceptable Conditions:** Grossly hemolyzed, lipemic, and/or icteric specimens

**Remarks:**

**Stability:** Room Temperature: 24 hours; Refrigerated: 1 month; Frozen: 1 month

**Methodology:**

**Performed:** Sun-Sat

**Reported:** 1-3 days

**Note:** This test should not be used for a woman with a multiple pregnancy (i.e., pregnancy with more than one fetus). This test should also not be used in pregnant women who received intravenous heparin within 24 hours.

**CPT Codes:** 83520 x2

**New York DOH Approval Status:** This test is New York DOH approved.

**Interpretive Data:**

The sFlt-1/PIGF ratio is indicated to be used as an aid in the management of the patient and is a prognostic assay intended to stratify hospitalized patients into two risk groups (low risk and high risk of progression to preeclampsia with severe features within two weeks from presentation).

The clinical cutoff for the sFlt-1/PIGF ratio is 40.

If the result of the ratio is greater than or equal to 40, the pregnant woman would be at high risk for progression to preeclampsia with severe features within 2 weeks.

If the result of the ratio is less than 40, the pregnant woman would be at low risk for progression to preeclampsia with severe features within 2 weeks.

The assay results should only be used in conjunction with information available from clinical evaluations and other standard of care procedures. The test result is not to be used to replace clinical judgment.

Reference Interval:

A sFlt-1/PIGF ratio greater than or equal to 40 is consistent with high risk for progression to preeclampsia with severe features within 2 weeks of presentation.

---

HOTLINE NOTE: Refer to the Hotline Test Mix for interface build information.